Cyxone’s Investigational T20K Therapy Shows Potential for Treating IBD in Preclinical Study

Cyxone’s Investigational T20K Therapy Shows Potential for Treating IBD in Preclinical Study
A preclinical study found that Cyxone’s investigational T20K therapy was able to reduce the immune system’s activity in an animal model of inflammatory bowel disease (IBD), showing promise as a treatment for the disease.  T20K belongs to a family of natural peptides derived from plants called cyclotides. Researchers found that cyclotides are able to inhibit the cytokine interleukin-2 (IL-2), a messenger molecule that induces inflammation, halting the proliferation of the immune system's T-cells.  Results from the first phase of Cyxone’s pilot study testing T20K for the treatment of IBD indicate that the compound reduces the activity of T-cells, an effect observed in the lymph nodes of an animal model of acute IBD. T-cell activation is thought to be crucial for the exaggerated inflammatory response that occurs in IBD; therefore T20K's ability to suppress these cells' activity holds promise as a potential treatment for IBD. Cyxone will further investigate the clinical benefits of the therapy for IBD symptoms in a second phase using an animal model that more closely mimics the nature of the disease. "We feel encouraged that cyclotides seem to mitigate T-cell activity, which is very positive and of even greater importance
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *